
|Articles|September 10, 2015
Rob Fox
Author(s)Rob Fox
Advertisement
Rob works within the global business development team consulting with pharmaceutical and biotech companies to identify and implement strategic solutions to meet their global access needs.
With more than 13 years experience in managed access programmes; he has worked across a range of therapeutic areas including oncology, critical care, HIV and orphan diseases. In co-ordination with our regulatory, medical and operations teams, he has initiated and delivered more than 50 access programmes on behalf of our partners and is an expert in the complexities of global access throughout a product’s lifecycle.
He earned a BA honours degree in business economics from the University of Liverpool.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
2
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
3
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
4
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
5




